{"url_path":"/sec/crdf/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-305467-index.html","accession_number":"0001193125-26-305467","cik":"0001213037","ticker":"CRDF","issuer_name":"Cardiff Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-305467-index.html","primary_entity_key":"0001213037","primary_entity_name":"Cardiff Oncology, Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\n(d) Exhibits.\n\n4.1\n\n[Form of Common Warrant](crdf-ex4_1.htm)\n\n4.2\n\n[Form of Placement Agent Warrant](crdf-ex4_2.htm)\n\n5.1\n\n[Opinion of Sheppard, Mullin, Richter & Hampton LLP](crdf-ex5_1.htm)\n\n10.1\n\n[Form of Securities Purchase Agreement](crdf-ex10_1.htm)\n\n99.1\n\n[Press Release of Cardiff Oncology, Inc. dated July 15, 2026.](crdf-ex99_1.htm)\n\n \n\n3\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCARDIFF ONCOLOGY, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJuly 16, 2026\n\nBy:\n\n/s/ Mani Mohindru\n\n \n\n \n\n \n\nMani Mohindru\n\nChief Executive Officer\n\n \n\n4"}